CTI Lands Baxter As Pacritinib Partner To Try To Reach Finish Line

The beleaguered oncology company has inked a partnership for its third late-stage candidate with hopes of taking it through approval, unlike its last two attempts.

With two recently failed late-stage cancer candidates, CTI BioPharma Corp. is hoping that the third time is the charm -- the troubled biotech inked a global commercialization agreement with Baxter International Inc. that it believes is a validation of the direction it’s taking.

CTI announced Nov. 15 that it has fulfilled its promise to investors to find a partner for its Phase III...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

GDPR Clarity For Pharma: Industry Code Nears EU-Wide Approval After Six-Year Journey

 
• By 

The pharmaceutical industry is edging closer to EU-wide clarity on how the bloc’s data privacy rules can be applied consistently to clinical trials and pharmacovigilance activities.

UK Initiative Steps Up Efforts To Tackle Recruitment Bottlenecks In Dementia Trials

 

A government-backed program is working on improving the ability to run dementia clinical trials in the UK, and access to trials for participants.

New Advisory Group To Shape UK’s Simplified Informed Consent Process

 

Although the UK Health Research Authority’s initial proposal for simplified informed consent was rejected by stakeholders, it has yielded valuable insights into reducing trial burden and widening access

Research Advances And Filings Prompt EMA To Revise Alzheimer’s Trial Guideline

 

Following EU approval of the first disease-modifying treatment for Alzheimer’s disease, and with a second expected soon, the European Medicines Agency plans to update its guidance to support the design of state-of-the-art clinical trials for the disease and enhance drug development.

More from R&D